TrialArteriosclerosis, thrombosis, and vascular biology2016

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.

Karen C Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.